FULGENT GENETIC (NASDAQ:FLGT) announced its earnings results on Monday. The company reported $0.02 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.02, Bloomberg Earnings reports.

Shares of FULGENT GENETIC (NASDAQ FLGT) traded down 3.91% during midday trading on Monday, hitting $6.14. 33,380 shares of the company traded hands. The company has a 50-day moving average price of $6.34 and a 200-day moving average price of $9.21. FULGENT GENETIC has a 52 week low of $4.49 and a 52 week high of $13.90. The stock’s market capitalization is $108.63 million.

Separately, Zacks Investment Research downgraded shares of FULGENT GENETIC from a “hold” rating to a “sell” rating in a research report on Friday, May 12th.

TRADEMARK VIOLATION WARNING: “FULGENT GENETIC (NASDAQ:FLGT) Posts Earnings Results” was first posted by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/08/07/fulgent-genetic-nasdaqflgt-posts-earnings-results.html.

In other news, insider Ming Hsieh acquired 20,000 shares of FULGENT GENETIC stock in a transaction that occurred on Thursday, June 15th. The stock was purchased at an average price of $5.26 per share, for a total transaction of $105,200.00. Following the purchase, the insider now directly owns 6,482,244 shares in the company, valued at approximately $34,096,603.44. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.


Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.

Receive News & Ratings for FULGENT GENETIC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FULGENT GENETIC and related companies with MarketBeat.com's FREE daily email newsletter.